BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, September 24, 2023
Home » Blogs » BioWorld MedTech Perspectives » Acrimony, acronyms, and life inside the Beltway

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Acrimony, acronyms, and life inside the Beltway

July 10, 2014
By Mark McCarty
No Comments

Abandon all hope ... unless you speak governmentese.
Abandon all hope ... unless you speak governmentese.

It’s that fun time of even-numbered years again when events in Washington bog down with the impending congressional summer recess and the November elections hanging over the heads of nearly everyone in Congress. Despite that Damoclean discomfort, shouldn’t we be rewarded with a regular set of spending bills?

Apparently not.

As best as I can tell, Congress had passed no spending bills for fiscal 2015 on or about July 10, which means we’re almost certainly headed for another series of CRs, or continuing resolutions. The fate of H.R. 4800, the bill that would fund FDA, seems to be that of a paperweight made of – you guessed it – paper. How deliciously ironic.

As matters currently stand, Congress and President Obama are hard at work on a supplemental appropriation for the child migrant predicament. Thankfully the Ryan-Murray budget deal from December of last year puts the sequester on hold for the upcoming fiscal year. Otherwise, device makers would be watching a large amount of user fees going down the nation’s fiscal rabbit hole again.

Alphabet soup; OPPS floats to the surface

If you’re into a mind-bending level of detail, just read through the Medicare outpatient prospective payment system proposal (try saying that three times fast) for calendar year 2015. Not only is it called OPPS by insiders, it talks a lot about CPT and HCPCS (pronounced hick-picks if you’re among the coverage/reimbursement cognoscenti) codes and lots of fun things like that.

CMS posted this and the physician fee proposal July 3 in a vain attempt to ruin everyone’s Fourth of July weekend, but anyone in the cardiology business might want to read through this riveting 600-plus page document. The agency indicated it would like to compress six comprehensive ambulatory payment classification codes (C-APCs) for vascular procedures into three.

Among these are C-APCs 0082 and 0083, which deal with clogged coronary and non-coronary arteries. 0082 is the code for cleaning out the affected artery whereas 0083 applies to angioplasty and valvuloplasty. CMS floated a similar proposal for some electrophysiology codes, squishing another six codes into three, rendering four codes total for levels I through IV for defibrillators, pacemakers and “related devices.”

I won’t pretend to know enough about how this would work in practice to predict whether these proposals would create more headaches than they’d solve, but hospital administrators might think it’s a good thing any time you can reduce the number of codes.

Pronouncing “MPFS” without hurting yourself

What struck me about the Medicare physician fee schedule proposal (MPFS) for calendar 2015 was a discussion about 10- and 90-day global codes for surgical procedures. CMS spent a lot of time explaining the problems with the current set-up, including that the framework was established a couple of decades ago, and OIG has published two reports highlighting the difficulties with these “global” issues. So why tackle it now?

This might be the reason. The continued existence of these codes in their present form may “present obstacles to the adoption of new payment models,” the proposal said.

Not to make too fine a point of it, but the agency might have done the reader a favor and just said up front, “the current set-up stinks and we want to do more bundled payments.” That would have saved me a lot of time.

And while we’re at it … enough already with “next-generation” DNA sequencing. Why is it that every generation of sequencing technology is the next generation? What happened to the current generation?

One supposes I could just be grateful they’re not claiming their technology is “disruptive” anymore.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    BioWorld Science
    PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing